Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Student Research Committee, Virtual School of Medical Education and Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
BMC Infect Dis. 2024 Oct 10;24(1):1138. doi: 10.1186/s12879-024-10043-6.
Vaccination is considered as one of the most promising strategies to overcome the COVID-19 pandemic. However, it could be associated with rare but serious complications. In the present study, we aimed to review the clinical course and etiology of post COVID-19 vaccination meningitis.
After a systematic search in PubMed, Scopus, and Web of Sciences online databases as well as Google Scholar, documents were screened and qualified. Then data extraction was performed and the most frequent underlying agent of meningitis was found based on the reported cases.
Overall, 35 cases of post COVID-19 vaccination meningitis from 33 articles were included in the review. Among them, 12 cases had proven viral diagnosis and 23 of them were reported to be vaccine-induced. The most frequent viral pathogen among the cases was VZV. The most prevalent symptom was headache, and the most common time of appearance symptoms was one week after vaccination.
Overall, our study suggested meningitis as a critical but not devastating complication of COVID-19 vaccination. Almost all patients responded well to common agents used to manage viral or vaccine-induced meningitis. It is recommended to monitor patients with a history of chickenpox after COVID-19 vaccination regarding the development of meningitis.
接种疫苗被认为是克服 COVID-19 大流行的最有前途的策略之一。然而，它可能与罕见但严重的并发症有关。在本研究中，我们旨在回顾 COVID-19 疫苗接种后脑膜炎的临床过程和病因。
在对 PubMed、Scopus 和 Web of Sciences 在线数据库以及 Google Scholar 进行系统搜索后，对文献进行筛选和合格评估。然后进行数据提取，并根据报告的病例找到最常见的脑膜炎潜在病原体。
共有 33 篇文章中的 35 例 COVID-19 疫苗接种后脑膜炎病例纳入综述。其中，12 例有明确的病毒诊断，23 例被报告为疫苗诱导。病例中最常见的病毒病原体是 VZV。最常见的症状是头痛，症状出现的最常见时间是接种后一周。
总体而言，我们的研究表明，脑膜炎是 COVID-19 疫苗接种的一种严重但并非毁灭性的并发症。几乎所有患者对用于治疗病毒性或疫苗诱导性脑膜炎的常用药物均有良好反应。建议对有带状疱疹史的患者在 COVID-19 接种疫苗后监测脑膜炎的发生。
